Ascentage Pharma appoints Marina S. Bozilenko and Debra Yu as independent board members
Ascentage Pharma, a global biopharmaceutical company dedicated to discovering, developing, and delivering treatments for critical medical needs, particularly in the field of cancer, has exciting news to share. They have recently welcomed Ms. Marina S. Bozilenko and Dr. Debra Yu as independent non-executive directors of their board.
Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma, expressed his warm welcome to both Ms. Bozilenko and Dr. Yu, highlighting their extensive experience in finance, investment, business development, and strategic management within the biopharmaceutical industry. As Ascentage Pharma progresses in its global innovation strategy, the addition of these accomplished professionals to the board is seen as a significant step towards further growth.
Ms. Marina S. Bozilenko, currently leading as President, CEO, and Director at Biothea Pharma, and an independent director at Talphera, Inc., brings a wealth of expertise from her previous roles at esteemed institutions like William Blair & Co. LLC and Bear, Stearns & Co., Inc. Dr. Debra Yu, MD, serving as the Chief Operating Officer at Panacea Venture and a board member at MeiraGTx Holdings PLC, has a rich career history in healthcare investment banking and venture capitalism.
Ascentage Pharma, listed on the Main Board of the Stock Exchange of Hong Kong Limited, is focused on addressing unmet medical needs, particularly in malignancies. Their pipeline includes innovative drug candidates targeting key pathways in cancer, showcasing their commitment to developing impactful therapies. Olverembatinib, their lead asset for drug-resistant chronic myeloid leukemia, has received significant designations and approvals, reflecting the company’s dedication to advancing treatment options.
With numerous clinical trials and partnerships with leading biotechnology and pharmaceutical companies, Ascentage Pharma is well-positioned to make meaningful contributions to the field of oncology. Their mission to address clinical needs worldwide underscores their dedication to improving patient outcomes.
Looking ahead, Ascentage Pharma remains focused on strengthening their R&D capabilities and advancing clinical development programs to continue making a positive impact in the lives of patients globally. The addition of Ms. Bozilenko and Dr. Yu to the board marks an exciting chapter in the company’s journey towards further growth and innovation.
